APGE Apogee Therapeutics
- 47.770
- +0.620+1.31%
- 47.770
- 0.0000.00%
Apogee Therapeutics News
TD Cowen Maintains Apogee Therapeutics(APGE.US) With Buy Rating
Promising Potential of Apogee Therapeutics: A Buy Rating Backed by Innovative Pipeline and Strategic Approach
TD Cowen Sticks to Its Buy Rating for Apogee Therapeutics, Inc. (APGE)
Apogee Therapeutics Analyst Ratings
CCORF Maintains Apogee Therapeutics(APGE.US) With Buy Rating, Maintains Target Price $89
Analysts Offer Insights on Healthcare Companies: Apogee Therapeutics, Inc. (APGE) and TransMedics Group (TMDX)
Wedbush Adjusts Price Target on Apogee Therapeutics to $90 From $87, Maintains Outperform Rating
Guggenheim Maintains Apogee Therapeutics(APGE.US) With Buy Rating, Raises Target Price to $110
CCORF Initiates Apogee Therapeutics(APGE.US) With Buy Rating, Announces Target Price $89
Apogee Therapeutics Price Target Announced at $89.00/Share by Canaccord Genuity
Apogee Therapeutics Initiated at Buy by Canaccord Genuity
Apogee Therapeutics Analyst Ratings
BTIG Maintains Apogee Therapeutics(APGE.US) With Buy Rating, Maintains Target Price $100
TD Cowen Maintains Apogee Therapeutics(APGE.US) With Buy Rating
Promising Advancements and Strategic Positioning Propel Apogee Therapeutics, Inc. to a Buy Rating
BTIG Maintains Apogee Therapeutics(APGE.US) With Buy Rating, Raises Target Price to $100
TD Cowen Maintains Apogee Therapeutics(APGE.US) With Buy Rating
Apogee Therapeutics Price Target Maintained With a $87.00/Share by Wedbush
Apogee Therapeutics Analyst Ratings
BTIG Maintains Apogee Therapeutics(APGE.US) With Buy Rating, Maintains Target Price $81
No Data